IGM Biosciences, Inc. (NASDAQ:IGMS – Get Free Report) has earned a consensus recommendation of “Reduce” from the ten analysts ...

The biotech company also has a partnership with Sanofi (SNY) for the development, manufacture and commercialization of IgM antibody agonists against inflammation and immunology targets.

IGM Biosciences announced a strategic update to halt the development of two antibody therapies, imvotamab and IGM-2644, for autoimmune diseases due to insufficient results and strategic ...

particularly due to its early-stage development of novel IgM antibodies, which are yet to be proven as viable therapeutic ...

This includes imvotamab and its pair of bispecific antibodies. First, their randomized studies for the DR5 IgM antibody aplitabart was scuttled in favor of reprioritization toward autoimmunity.

and commercialize IgM antibody agonists against immunology and inflammation targets. For more information, please visit www.igmbio.com. Cautionary Note Regarding Forward-Looking Statements This ...

IGM's potential therapies are based off the company's approach tapping the immunoglobulin M, or IgM, antibody that is produced by the immune system to fight infections. Now IGM, according to its ...

The business is stopping further research on imvotamab, a CD20 x CD3 bispecific antibody, and IGM-2644, a CD38 x CD3 bispecific antibody. Phase 1b rheumatoid arthritis and systemic lupus ...

In yet another early year blow for the Bay Area’s biotech workforce, IGM Biosciences is laying off almost three-fourths of its staff after a crucial clinical study delivered poor results.